학술논문


EBSCO Discovery Service
발행년
-
(예 : 2010-2015)
전자자료 공정이용 안내

우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.

공정이용 지침
  • 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
  • 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
  • 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
  • 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
  • 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
  • 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
  • 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
  • 상업적·영리적 목적으로 자료를 전송·복제·활용
  • ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
  • EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
  • 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
  • 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
  • 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문' 에서 검색결과 654건 | 목록 1~20
Academic Journal
Fokkema C; Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Bertamini L; Erasmus MC Cancer Institute, Rotterdam, Netherlands.; de Jong MME; Erasmus MC Cancer institute, Rotterdam, Netherlands.; Tahri S; Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Hofste Op Bruinink D; Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Kellermayer Z; Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Papazian N; Erasmus MC, Rotterdam, Netherlands.; den Hollander C; Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Vermeulen M; Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Stoetman ECG; Erasmus MC Cancer Institute, Rotterdam, Netherlands.; van Beek G; Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Hoogenboezem R; Erasmus MC Cancer institute, Rotterdam, Netherlands.; van der Velden VHJ; Erasmus MC, Rotterdam, Netherlands.; Hulin C; CHU Bordeaux, Hopital haut Leveque, centre François Magendie, PESSAC, France.; Perrot A; Université de Toulouse, CHU Toulouse, Toulouse, France.; Moreau P; Hematology, University Hospital Hôtel-Dieu, Nantes, France.; Rowe M; Johnson & Johnson, High Wycombe, UK, United Kingdom.; Vieyra D; Janssen Research & Development, LLC, Spring House, Pennsylvania, United States.; Carson R; Johnson & Johnson, High Wycombe, UK, United Kingdom.; van Duin M; Erasmus MC Cancer institute, Rotterdam, Netherlands.; Sanders MA; Erasmus MC Cancer institute, Rotterdam, Netherlands.; Broijl A; Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Sonneveld P; Erasmus MC Cancer institute, Rotterdam, Netherlands.; Cupedo T; Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Academic Journal
Kellermayer Z; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; Tahri S; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; de Jong MME; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; Papazian N; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; Fokkema C; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; Stoetman ECG; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; Hoogenboezem R; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; van Beek G; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; Sanders MA; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; Boon L; JJP Biologics Warsaw Poland.; Den Hollander C; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; Broijl A; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.; Cupedo T; Department of Hematology, Erasmus MC Cancer Institute Erasmus Medical Center Rotterdam The Netherlands.
Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE
B01 | ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE WITH OR WITHOUT ISATUXIMAB (PHASE III ISKIA TRIAL): F. Gay1, W. Roeloffzen2, M.A. Dimopoulos3|4, L. Rosiñol5, M. Van Der Klift6, A. Oriol7, E. Katodritou8, K. L. Wu9, P. Rodríguez Otero10, R. Hájek11|12, I. Attucci13, E. Zamagni14|15, M. Van Duin16, M. D'Agostino1, A. Belotti17, S. Mangiacavalli18, M. Grasso19, G. Margiotta Casaluci20, M. Offidani21, G.M. De Sabbata22, F. Fioritoni23, P. Tosi24, P. Musto25|26, F. Schjesvold27|28, J. Bladé5, H. Einsele29, P. Sonneveld16, M. Boccadoro30, A. Broijl16. | 1Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino; 2Department of Hematology, University Medical Center Groningen; 3Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens; 4Department of Medicine, Korea University; 5Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic de Barcelona, IDIBAPS, and PETHEMA/GEM; 6Department of Internal Medicine, Amphia Hospital; 7Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol; 8Department of Hematology, Theagenion Cancer Hospital; 9ZNA Cadix; 10Cancer Center Clínica Universidad de Navarra; 11Department of Haematooncology, University Hospital Ostrava; 12Department of Haematooncology, Faculty of Medicine, University of Ostrava; 13Hematology Unit, AOU Careggi; 14IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; 15Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna; 16Department of Hematology, Erasmus MC Cancer Institute; 17Department of Hematology, ASST Spedali Civili di Brescia; 18Division of Hematology, Fondazione IRCCS Policlinico San Matteo; 19SC Ematologia, Azienda Ospedaliera Santa Croce e Carle; 20AOU Maggiore della Carità; 21AOU delle Marche, Università Politecnica delle Marche; 22Ematologia, Azienda sanitaria universitaria Giuliano Isontina; 23UOC Ematologia Pescara; 24Hematology Unit, Infermi Hospital; 25Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine; 26Hematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico; 27Oslo Myeloma Center, Department of Hematology, Oslo University Hospital; 28KG Jebsen Center for B cell malignancies, University of Oslo; 29Department of Internal Medicine II, University Hospital Würzburg; 30European Myeloma Network - EMN
Academic Journal
van de Donk NWCJ; Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.; Cancer Center Amsterdam Cancer Biology and Immunology Amsterdam The Netherlands.; Moreau P; Department of Hematology University Hospital Hôtel-Dieu Nantes France.; San-Miguel JF; Cancer Center Clinica Universidad de Navarra CIMA, IDISNA, CIBERONC Pamplona Spain.; Mateos MV; Cancer Research Center University Hospital of Salamanca, IBSAL Salamanca Spain.; Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine National and Kapodistrian University of Athens Athens Greece.; Department of Medicine Korea University Seoul South Korea.; Zweegman S; Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.; Cancer Center Amsterdam Cancer Biology and Immunology Amsterdam The Netherlands.; Gay F; University Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy & Department of Biotechnology and Health Sciences University of Torino Italy.; Engelhardt M; Department of Hematology and Oncology, Interdisciplinary Cancer Center and Comprehensive Cancer Center Freiburg University of Freiburg, Faculty of Freiburg Freiburg Germany.; Mina R; University Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy & Department of Biotechnology and Health Sciences University of Torino Italy.; Zamagni E; IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 'Seràgnoli' Bologna Italy.; Dipartimento di Scienze Mediche e Chirurgiche Università di Bologna Bologna Italy.; Delforge M; Department of Hematology University Hospital Leuven Leuven Belgium.; Beksac M; Ankara Liv Hospital Istinye University Ankara Turkey.; Spencer A; Alfred Health-Monash University Melbourne Victoria Australia.; Schjesvold F; Oslo Myeloma Center, Department of Hematology Oslo University Hospital Oslo Norway.; Driessen C; Department of Medical Oncology and Hematology, HOCH Health Ostschweiz Cantonal Hospital St. Gallen St. Gallen Switzerland.; Kaiser M; Department of Hematology, The Royal Marsden Hospital & Division of Genetics and Epidemiology The Institute of Cancer Research London United Kingdom.; Perrot A; Université de Toulouse, Centre Hospital-Universitaire Institut Universitaire du Cancer Toulouse Oncopole Toulouse France.; Wäsch R; Department of Hematology and Oncology, Interdisciplinary Cancer Center and Comprehensive Cancer Center Freiburg University of Freiburg, Faculty of Freiburg Freiburg Germany.; Korst CLBM; Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.; Cancer Center Amsterdam Cancer Biology and Immunology Amsterdam The Netherlands.; Broijl A; Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands.; Touzeau C; Department of Hematology University Hospital Hôtel-Dieu Nantes France.; Manier S; Department of Hematology Lille University Hospital and INSERM UMR-S1277 and CNRS UMR9020 Lille France.; Hajek R; Department of Hemato-Oncology University Hospital Ostrava Ostrava Czech Republic.; Department of Hemato-Oncology, Faculty of Medicine University of Ostrava Ostrava Czech Republic.; Bila J; Clinic of Hematology, University Clinical Center of Serbia, Medical Faculty University of Belgrade Belgrade Serbia.; Seval GC; Department of Hematology Ankara University Faculty of Medicine Ankara Turkey.; O'Dwyer M; Department of Medicine/Haematology University of Galway Galway Republic of Ireland.; Ludwig H; Wilhelminen Cancer Research Institute, First Department of Medicine Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring Vienna Austria.; Fernandez de Larrea C; Hospital Clínic de Barcelona. IDIBAPS University of Barcelona Barcelona Spain.; Popat R; Department of Haematology University College London Hospitals NHS Foundation Trust London United Kingdom.; Musto P; Department of Precision and Regenerative Medicine and Ionian Area 'Aldo Moro' University School of Medicine Bari Italy.; Hematology and Stem Cell Transplantation Unit AOU Consorziale Policlinico Bari Italy.; Rodriguez-Otero P; Cancer Center Clinica Universidad de Navarra CIMA, IDISNA, CIBERONC Pamplona Spain.; Yong K; Department of Haematology University College London Hospitals NHS Foundation Trust London United Kingdom.; Kortüm M; Department of Internal Medicine II University Hospital of Würzburg Würzburg Germany.; Rasche L; Department of Internal Medicine II University Hospital of Würzburg Würzburg Germany.; Terpos E; Department of Clinical Therapeutics, School of Medicine National and Kapodistrian University of Athens Athens Greece.; Raab MS; Heidelberg Myeloma Center, Department of Internal Medicine V Heidelberg University Hospital and Medical Faculty Heidelberg Germany.; Boccadoro M; Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy.; European Myeloma Network (EMN) Torino Italy.; Sonneveld P; Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands.; Einsele H; Department of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE
Academic Journal
Raab MS; Heidelberg Myeloma Center, Department of Medicine V University Hospital Heidelberg Germany.; Zamagni E; Seragnoli Institute of Hematology Bologna University School of Medicine Bologna Italy.; Manier S; Department of Hematology University Hospital Center of Lille Lille France.; Rodriguez-Otero P; Department of Hematology Clinica Universidad de Navarra Madrid Spain.; Schjesvold F; Oslo Myeloma Center, Department of Haematology Oslo University Hospital, Oslo, Norway, and KG Jebsen Center for B Cell Malignancies University of Oslo Oslo Norway.; Broijl A; Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands.
Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101761942 Publication Model: eCollection Cited Medium: Internet ISSN: 2688-6146 (Electronic) Linking ISSN: 26886146 NLM ISO Abbreviation: EJHaem Subsets: PubMed not MEDLINE
Academic Journal
Moreau, P, Hulin, C, Perrot, A, Arnulf, B, Belhadj, K, Benboubker, L, Zweegman, S, Caillon, H L, Caillot, D, Avet-Loiseau, H, Delforge, M, Dejoie, T, Facon, T, Sonntag, C C, Fontan, J, Mohty, M, Jie, K-S, Karlin, L, Kuhnowski, F, Lambert, J R, Leleu, X, Macro, M, Orsini-Piocelle, F, Roussel, M, Schiano de Colella, J M, van de Donk, N W CJ, Wuillème, S, Broijl, A, Touzeau, C, Tiab, M, Marolleau, J-P, Meuleman, N, Vekemans, M-C, Westerman, M, Klein, S K, Levin, M-D, Offner, F, Escoffre-Barbe, M, Eveillard, J-R, Garidi, R D, Hua, W, Wang, J, Tuozzo, A, de Boer, C, Rowe, M & Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators 2024, 'Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma : long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial', The Lancet Oncology, vol. 25, no. 8, pp. 1003-1014. https://doi.org/10.1016/S1470-2045(24)00282-1
The Lancet. Oncology, Vol. 25, no.8, p. 1003-1014 (2024)
검색 결과 제한하기
제한된 항목
[검색어] Broijl, A.
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어